Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

Slides:

Advertisements

Similar presentations

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Advertisements

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

Fig. 6. Mucus analysis of lungs from allergic and tolerized mice

Expression of p110γ isoform in macrophages promotes tumor growth and angiogenesis. Expression of p110γ isoform in macrophages promotes tumor growth and.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Interacting MDSCs and mast cells (MC) in human colon carcinoma and in the colon of AOM/DSS-induced tumor-bearing mice. Interacting MDSCs and mast cells.

Autophagy restrains pancreatic inflammation and expression of pTBK1, CCL5, and PD-L1 in vivo. Autophagy restrains pancreatic inflammation and expression.

IL32 is highly expressed in mycosis fungoides lesional skin.

Subcutaneous tumor growth was significantly increased in Ogt-Tg/+ mice

GC reaction is impaired in NOTCH2 knock-in mice.

Stereotactic radiotherapy increases Tregs in tumors.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Antigen-specific CD8+ T cells express higher levels of PD-1 in animals that received the optimized SSX2 vaccine. Antigen-specific CD8+ T cells express.

Fig. 4. The inhibition of mast cell infiltration by topical application of the TECA + AST combination in dorsal ear and back skin. Mast cell infiltrations.

Dose-dependent effect of IP6 feeding on molecules associated with tumor sustenance and glucose transportation in dorsolateral prostate of TRAMP mice. Dose-dependent.

Anti-Flk-1 mAb treatment reduces vessel density in tumors.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo. EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Activation of Ccl2–Ccr2 pathway is required for mammary carcinogenesis induced by Rb deficiency. Activation of Ccl2–Ccr2 pathway is required for mammary.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Intratumoral lymphoid aggregates are sites of postvaccination T-cell activation and regulation. Intratumoral lymphoid aggregates are sites of postvaccination.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

HMQ1611 inhibited breast tumor growth in mice.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

A and B, intratumoral DC-AdCCL21 leads to reduction in growth rates of bilateral tumors. A and B, intratumoral DC-AdCCL21 leads to reduction in growth.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Effect of CDV on human SF7796 xenografts in vivo.

Expression of PCNA, K10, and K5 in skin lesions from Stat3+/−:HPV8 and Stat3+/+:HPV8 mice. Expression of PCNA, K10, and K5 in skin lesions from Stat3+/−:HPV8.

The effect of a DIO regimen ± EPA+DHA supplementation on tumor growth.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Pomalidomide decreases fibrosis in the lesion areas of the pancreas of KC mice. Pomalidomide decreases fibrosis in the lesion areas of the pancreas of.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Comparative effect of anti-TIM3 against experimental tumors.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

In vivo effects of TTFields on intradermal tumors in mice.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

PDL192 and inhibit the growth of xenograft tumors.

Effects of ZOL treatment on pulmonary metastases.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

GCS-100 selectively kills KRAS-addicted lung tumors.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells. Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells.

CD36 expression is coordinately regulated in multiple cellular compartments. CD36 expression is coordinately regulated in multiple cellular compartments.

CD36 expression in tissue adjacent and distal to the tumor.

Curative effect of W+T treatment in vivo.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3 pathway. TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3.

PEGPH20 depletes HA and decompresses intratumoral vessels.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Trametinib and combination decrease T-lymphocyte proliferation.

Presentation transcript:

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. A, effect of antiangiogenic TKIs, vaccine, and their combination on tumor compactness. CEA-Tg mice (n = 3/group) bearing subcutaneous MC38-CEA tumors were treated as described in Fig. 1. H&E-stained tumor sections at ×10 magnification show tumor compactness. Less-compact areas are outlined in black. B, IHC analysis of tumor sections stained for the tight-junction–associated JAM-A; scale bars, 10 μm. Bright fields at ×100; black arrows, intercellular JAM-A; i, internalized JAM-A; pie charts, digital analysis of JAM-A expression. Statistical analysis based on the t test compared with control; bold numbers, statistically significant difference (P < 0.05). C, cell density in packed areas (P) was higher than in unpacked areas (U) of tumor, independent of treatment; columns, averages of packed or unpacked tumor area for each treatment; bars, SEM. Statistical analysis based on the t test comparing packed and unpacked areas with each treatment. D, each individual treatment and the combination of TKI plus vaccine increased the extent of unpacked tumor area; columns, averages of unpacked tumor areas; bars, SEM. Statistically significant differences based on ANOVA. E, intratumoral pressure analysis of MC38-CEA tumors from CEA-Tg mice (n = 15–20/group from two independent experiments) treated as described in Fig. 1. F, intratumoral pressure was measured on days 21, 26, and 31 after tumor transplant. Right graph, CEA-Tg B57BL/6 mice (n = 7–10/group) bearing subcutaneous MC38-CEA tumors were vaccinated with rMVA–CEA–TRICOM, WT-MVA, or left untreated. Intratumoral pressure was measured 21 days after tumor transplant. Statistically significant differences based on ANOVA: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Benedetto Farsaci et al. Cancer Immunol Res 2014;2:1090-1102 ©2014 by American Association for Cancer Research